Angiolite BTK
Sirolimus eluting peripheral stent
PRODUCT FEATURES
Stent Design
High radial force with mínimum recoil to be able to treat BTK lesions.
Specifically designed for homogeneous arterial coverage.
Coating technology
TransferWise, the iVascular proprietary technology that provides a homogenous drug elution that translates into lower rates of restenosis and inflammation score. Our fluoro-acrylate polymer provides an early endothelialization and creates a thromboresistant layer. This mechanism suggest to reduce stent thrombosis.
Clinical Support
Angiolite BTK has demonstrated its safety and efficacy in the following clinical trial:
ANGIOLITE BTK Trial
Prospective, real-life trial in BTK lesions.
at 6 months.
MERLION Trial
Prospective, non-randomized multicenter trial in TASC C and D tibial occlusive disease with CLI.
at 1-year
Speak to the team
Our office is open Monday - Friday 8.30am - 5.00pm
Feel free to get in touch direct or leave us a message on the contact form and the team will get back to you